Press releases

26 October, 2016

Regulatory

NeuroVive Pharmaceutical AB: Annual General Meeting 2017 and Nomination Committee

Lund, Sweden, October 26, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the Annual General Meeting of NeuroVive Pha ...

25 October, 2016

Regulatory

NeuroVive completes closure of Lyon subsidiary

Lund, Sweden, October 25, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that it has completed the closure of its dormant ...

21 October, 2016

Regulatory

NeuroVive and Arbutus sign termination agreement

Lund, Sweden, October 21, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the license agreement with Arbutus Biopharm ...

13 October, 2016

Regulatory

NeuroVive discontinues development of CicloMulsion for acute kidney injury

Lund, Sweden, October 13, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced results from the exploratory clinical phase II s ...

7 September, 2016

Regulatory

NeuroVive to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

Lund, Sweden, September 7, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the company is scheduled to present at the ...

30 August, 2016

Regulatory

NeuroVive announces that the clinical study CiPRICS will be presented at the Swedish Thorax meeting in October 2016

Lund, Sweden, August 30, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the clinical study CiPRICS will be presented ...

24 August, 2016

Regulatory

NeuroVive’s Chief Operating Officer Jan Nilsson leaves the company

Lund, Sweden, August 24, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that its Chief Operating Officer, Jan Nilsson lea ...

18 August, 2016

Regulatory

NeuroVive Pharmaceutical – Interim report January-June 2016

Business operations

15 August, 2016

Regulatory

NeuroVive completes 10 percent acquisition of Isomerase Therapeutics

Lund, Sweden, August 15, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the second step in the previously announced ...

9 August, 2016

Regulatory

NeuroVive’s novel strategy for treatment of mitochondrial disease published in Nature Communications

Lund, Sweden, August 9, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that research results from the NVP015 program inve ...

6 July, 2016

Regulatory

NeuroVive announces Arbutus Biopharma’s notice of termination

Lund, Sweden, July 6, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that Arbutus Biopharma (formerly OnCore Biopharma, I ...

7 June, 2016

Regulatory

NeuroVive announces CiPRICS study completes enrolment

Lund, Sweden, 7 June 2016 - NeuroVive Pharmaceutical AB (publ), announces that the CiPRICS (Ciclosporin to Protect Renal function In Cardiac Surgery) clinical research team at the Department of Cardio ...